
Evotec
Evotec are a R&D biotech that offers accelerating, high value pipeline co-creation partnerships and comprehensive CRO/CDMO services – always striving for highest quality, capital efficient execution of R&D programs from disease understanding towards IND, Phase 1, and beyond. Our expertise spans across therapeutic/disease areas and most modalities, especially small molecules and biotherapeutics. We take pride in acting as "drug hunters" in deep collaboration with our partners to advance science. At the core of our operations are our industrialized, AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies. These platforms are instrumental in enhancing disease understanding and ensuring human relevance in our research. By integrating AI and continuous manufacturing technology, we facilitate better access to high-quality biotherapeutics, revolutionizing the way treatments are developed and produced.
Latest Evotec Content

The Promise of Continuous Processing To Advance Biopharmaceutical Production

Evotec Receives Grant From Korean Government To Develop Novel Antibody-Based Treatments for Lung Diseases

Evotec SE Announces First Projects for LAB eN² Drug Discovery Accelerator With Novo Nordisk

Spatial Transcriptomics in Neuroscience

Harnessing Structural Insights in Drug Discovery

Therapeutic siRNAs: Considerations for “Picking the Best One”

Trends in Target-Based Drug Discovery

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

High-Sensitivity Proteomics: The Next Frontier for Spatial and Single-Cell Biology
